Lifespan vs Healthspan: An Evidence-Based Introduction to Longevity

By Anas, Editor at HealthForge · Published 13 July 2026 · 18 min read

By the HealthForge Editorial Team · Reviewed against primary sources · Last updated 2026

The average person now dies about a decade after their body stops working well. Across all 183 World Health Organization member states, people spend roughly 9.6 years living with meaningful disease or disability before death — and that gap has widened over the past two decades rather than narrowed².

That single figure sits at the heart of modern longevity science. Lifespan measures how long you live. Healthspan measures how long you live well. The two have drifted apart, and closing the distance between them has become one of the more consequential questions in aging research.

What follows clarifies the definitions, walks through the newest data on the gap, and separates the evidence-backed levers from the speculative ones.

In this article

1. The short version
2. Lifespan vs Healthspan: The Core Definitions
3. The Global Healthspan Gap: 9.6 Years and Rising
4. Why the Gap Matters: Quality Over Quantity
5. Gender and Regional Disparities
6. The Pillars of Healthspan Extension
7. Beyond Lifestyle: Emerging Longevity Interventions
8. How to Track and Improve Your Personal Healthspan
9. What this means for you
10. What we still don’t know
11. Common questions
12. Where this leaves us
13. Related reading

Lifespan vs Healthspan: The Core Definitions

Lifespan is the simpler of the two: the total number of years a person is alive.

Healthspan is how many of those years are spent in good health — free from the chronic diseases and functional decline that erode independence and quality of life. A 2016 JAMA Internal Medicine review, which helped popularize the term, defined it as years lived without disease or disability¹.

Precision is the sticking point. A 2025 analysis in Nature Communications Medicine counted 113 different definitions of “healthspan” across the systematic-review literature³. Some studies mark its end at the first diagnosis of a chronic condition; others use functional decline — the point where someone can no longer climb stairs, dress, or live independently. Where you draw the line changes the size of the gap you measure.

To sidestep that inconsistency, epidemiologists often lean on the WHO’s Health-Adjusted Life Expectancy (HALE) — the years a population can expect to live in full health. In this framing, the healthspan-lifespan gap is simply life expectancy minus HALE.

Where “longevity” fits

Longevity is the broader umbrella term for living long. In practice, the field’s emphasis has shifted: the goal is no longer just more years but more good ones. As a 2021 Nature Aging paper noted, life expectancy has risen by roughly 30 years since the mid-20th century, while healthspan has not expanded to match⁸.

The Global Healthspan Gap: 9.6 Years and Rising

The most rigorous number available comes from a 2024 JAMA Network Open study of all 183 WHO member states. Its global mean healthspan-lifespan gap sits at 9.6 years, and the gap widened across every single member state over the two decades studied².

We have not compressed morbidity — the medical ideal of squeezing sickness into a shorter window at the very end of life. The 2016 JAMA Internal Medicine review stated the uncomfortable conclusion plainly: true morbidity compression has not occurred, because our success at reducing mortality has outpaced our success at preventing disease¹. We have added years, and a disproportionate share of them are years of illness.

No country has escaped this. A 2025 Nature Communications Medicine analysis confirmed that not one nation has closed the gap between life expectancy and HALE³.

The US outlier

Among all countries the WHO tracks, the United States carries the largest gap, at 12.4 years²³. Americans, on average, spend more than a decade in poor health before death — the widest margin recorded. That pattern reflects a heavy noncommunicable disease burden layered onto relatively high life expectancy.

Why the Gap Matters: Quality Over Quantity

This is a structural problem, not only a personal misfortune.

Chronic disease dominates the cost. A 2023 Frontiers in Public Health analysis found that cardiovascular disease (30.3%) and cancers (15.1%) are the leading contributors to medical expenses in older adults, with costs climbing steeply as people age and approach death²².

Those costs ripple outward. A 2022 econometric study estimated that every 1% rise in healthcare burden corresponds to a 0.083% drop in GDP growth, mediated partly by working-age people leaving jobs to care for sick relatives²⁰.

The potential upside of closing the gap is large, though harder to pin down. A 2021 Nature Aging modeling paper put the economic value of slowing aging enough to add one year of life expectancy at roughly US$38 trillion, and ten years at US$367 trillion — with most of that value coming from compressed morbidity rather than extra years of disability²¹. These are projections from a value-of-statistical-life model, not measured outcomes; they assume gains flow from delaying aging broadly rather than treating one disease at a time. Read cautiously, they still explain why healthspan has become a policy question and not only a personal one.

Gender and Regional Disparities

The gap is universal but far from uniform.

Women outlive men in most countries, yet they carry a larger healthspan-lifespan gap — about 2.4 years wider than men’s, a difference driven disproportionately by noncommunicable disease burden². Longer life, in this case, comes with more years of managed illness.

Look closely, though, and the picture grows more complicated. A 2025 BMJ Open study found gender gaps in disability-free life expectancy ranging from −0.37 years in Portugal to 4.9 years in South Korea⁶. Its authors caution against reading these gaps as simple measures of inequality: South Korea’s large gap, for instance, reflects a survival advantage that outweighs the disability disadvantage roughly thirteenfold. Treating the healthy-life-expectancy gender gap as a proxy for inequality, they argue, hides the underlying mortality and health differences⁶.

Regionally, a 2025 Nature Communications Medicine study showed the gap varies with life expectancy, GDP, and noncommunicable disease burden⁴. Africa shows the narrowest gap of any region — alongside the fastest expansion and the most rapid shift in disease burden as infectious diseases give way to chronic ones⁵. Wealthier, longer-lived regions have simply had more time to accumulate the chronic-disease burden that widens the gap.

The Pillars of Healthspan Extension

Before the experimental drugs, a reminder of where the strongest evidence sits: ordinary lifestyle behavior.

A 2021 EBioMedicine study identified ten routine clinical biomarkers — spanning glucose regulation, lipids, inflammation, and blood measures — significantly associated with both healthspan and lifespan²³. Most exerted their influence by shaping the risk of several age-related diseases at once. Because these markers respond to diet and exercise, the authors framed lifestyle intervention as a route to better healthspan that does not depend on experimental geroprotective drugs²³.

The practical pillars are familiar ones:

• Movement and strength. Muscle mass and physical capability rank among the clearest predictors of functional independence in later life. Resistance training and consistent daily activity both matter, and structured exercise for healthspan is one of the most reliable ways to move the biomarkers above.
• Reducing sedentary time. Chronic sitting undermines metabolic and vascular health independent of formal exercise. Breaking up long stretches of stillness helps.
• Sleep. Poor sleep tracks with inflammatory and metabolic markers tied to accelerated aging, and the link between sleep and health runs through chronic disease and mortality risk.
• Metabolic health. The glycemic and lipid markers linked to healthspan are the same ones targeted by dietary quality; an evidence-based nutrition framework is the most practical way to move them in the right direction²³.
• Managing chronic stress and inflammation. Allostatic load — the cumulative wear of stress — is among the strongest predictors of frailty and cardiovascular risk (more on that below)⁹.
• Cognitive and social engagement. Cognitive decline is a major driver of lost healthspan, not a footnote to it.

For desk-bound readers, cutting sedentary time is one of the more actionable levers. A sit-stand setup can make it easier to interrupt long stretches of sitting; the Adjustable Ergonomic Desk with Seat Pad is one such option (an affiliate product), though any standing desk or simple movement break serves the same purpose.

Beyond Lifestyle: Emerging Longevity Interventions

Here the attention runs highest and the evidence thinnest. Almost all of it comes from animals or short-term human trials — which is why it pays to know how to read health research using the evidence hierarchy before treating any of these findings as settled.

Rapamycin and metformin

A 2025 meta-analysis in Aging Cell pooled 167 papers across eight vertebrate species. Rapamycin produced significant lifespan extension comparable to dietary restriction. Metformin, despite its popularity in longevity circles, showed no consistent lifespan extension across species¹². So the drug most people have heard of turns out to have the weaker animal evidence.

Both are being studied for cardiac aging through metabolic regulation, though a 2025 cardiovascular review stressed that long-term safety questions remain unresolved¹⁵.

Senolytics

Senolytics aim to clear senescent “zombie” cells, which accumulate with age and drive inflammation. The most-studied combination is dasatinib plus quercetin.

The human evidence is early but real. A 2019 EBioMedicine randomized trial showed that dasatinib plus quercetin reduced the burden of senescent cells in adipose tissue within 11 days in people with diabetic kidney disease — confirming senolytic activity in humans¹³. In middle-aged nonhuman primates, a 2023 Geroscience study found that six months of intermittent dosing was safe and improved senescence markers, immune profiles, and metabolic health¹⁴.

These are proof-of-concept findings, not a green light for healthy people. Dasatinib is a potent chemotherapy drug approved for leukemia, with recognized cardiac, pulmonary, and bleeding risks; none of these compounds is an approved healthspan therapy, and the case for using them outside a trial in an otherwise healthy adult has not been made.

Steepening the curve vs scaling it

A 2025 Nature Communications modeling paper drew a useful distinction. Interventions that steepen the survival curve — by increasing the rate at which the body clears damage — compress relative sickspan and genuinely extend healthspan. Interventions that merely scale the curve, such as caloric restriction, tend to extend the sick period proportionally without compressing it⁷. In short, adding years does not automatically add healthy years. The framework is theoretical, but clarifying.

How to Track and Improve Your Personal Healthspan

The honest answer to “how do I measure my healthspan?” is that the science is still maturing.

Our most consistent longitudinal signal comes from a 2025 Communications Medicine study of 1,083 people followed for 7.4 years. Two measures stood out: DunedinPACE, an epigenetic clock estimating the pace of aging, and the Allostatic Load Index, a composite of inflammatory and stress markers. Both showed the strongest and most consistent associations with frailty, metabolic syndrome, and cardiovascular risk, and adding them improved clinical prediction models by up to 24 percentage points in this single cohort⁹.

Expert opinion is converging on similar ground. A 2025 consensus statement in the Journals of Gerontology identified 14 validated biomarkers across physiological, inflammatory, functional, and epigenetic domains for use in longevity intervention studies²⁴. An earlier proposed panel spanned five domains — physical capability, cognition, physiological and musculoskeletal function, endocrine, and immune markers — with inflammatory factors flagged as especially relevant to cognitive decline²⁵.

The cognitive dimension

Cognition is a large and often underweighted part of healthspan. Several blood-based markers now show real predictive value:

• Plasma-based brain age. A 2025 Nature Aging study reported that accelerated brain aging measured in blood carried the strongest association with Alzheimer’s risk among biological-age measures (hazard ratio 1.79)¹⁶.
• Neurofilament light chain (NfL). This marker of neuronal damage predicts incident cognitive decline and correlates with worse executive function¹⁷.
• Epigenetic age. Blood epigenetic age predicts future cognitive decline and dementia in some studies, though results vary¹⁸.

A body-brain connection runs through all of this: a 2025 review in Clinical Interventions in Aging described how peripheral changes — adipose-derived inflammation and vascular dysfunction — feed into cognitive decline¹⁹. What protects the heart tends to protect the brain.

A caution on the tools

Two things temper the enthusiasm. Most biomarker validation still rests on observational cohorts; a 2024 Nature Medicine review noted that prospective clinical trials are needed before these markers can be said to guide better outcomes¹⁰. And the field lacks standardization — a 2024 Nature Medicine framework called for multi-omic approaches and a shift away from mortality alone toward functional decline, frailty, and chronic disease as endpoints¹¹.

Consumer wearables and sleep trackers can help you monitor the behaviors underneath these markers — sleep consistency, heart-rate variability, activity — even if they don’t measure biological age directly.

What this means for you

The most defensible reading of the evidence is straightforward: the interventions with the strongest human support are behavioral. The ten clinical biomarkers most tied to healthspan respond to diet and exercise²³, and the two most predictive aging measures track inflammation, stress, and metabolic health⁹ — all of which you can influence.

In practice, that means preserving muscle and physical capability, protecting sleep, keeping metabolic markers in healthy ranges, and reducing chronic stress and prolonged sitting. These are the levers the data reward.

Readers who want a longer synthesis of this healthspan-first framing may find Peter Attia’s Outlive a readable overview grounded in the same research.

Treat experimental compounds — rapamycin, metformin, senolytics — as active research rather than personal recommendations. Their evidence base is largely preclinical or short-term, and several carry real risks. Any consideration of them belongs in a conversation with a physician.

What we still don’t know

The evidence has real boundaries worth stating plainly.

Healthspan itself is not measured consistently — 113 competing definitions mean gap figures depend heavily on methodology³. The 9.6-year and 12.4-year numbers are robust population averages, but they cannot tell any individual how their own years will divide between health and illness.

Most of the drug evidence is not human. Rapamycin’s lifespan data come from animals across species¹²; senolytic human data are limited to small, short trials in people who were already ill¹³. None of this establishes that these agents extend healthspan in healthy adults, and long-term safety is unresolved¹⁵.

Biomarker tools are promising but not yet clinically validated. Most rest on observational data, and the field openly acknowledges that prospective trials are needed before these measures can guide decisions¹⁰¹¹. The economic figures — the trillions attributed to slowing aging — are modeling estimates that stand or fall with their assumptions²¹.

Correlation is also not causation. Biomarkers associated with healthspan may reflect underlying health rather than cause it, and much of the framing around “steepening the survival curve” remains theoretical⁷.

Common questions

What is the average gap between lifespan and healthspan?

Globally, about 9.6 years, based on a 2024 analysis of all 183 WHO member states². The figure varies widely by country — the United States has the largest gap at 12.4 years²³ — and depends on how healthspan is defined, since researchers have used more than 100 different definitions³.

Can you live longer without living healthier?

Yes, and that is precisely the problem the field is trying to solve. Life expectancy has risen by roughly 30 years since the mid-20th century, but healthspan has not kept pace⁸. Mortality reductions have outrun disease prevention, so the extra years skew toward illness rather than health¹.

Is healthspan more important than lifespan?

Research increasingly frames them as complementary, with healthspan as the priority. The economic value of longevity interventions comes overwhelmingly from compressing morbidity — reducing years lived with disability — rather than simply adding years²¹. More years matter most when they are healthy ones.

Does the gap differ by gender or region?

Yes to both. Women have a gap about 2.4 years wider than men’s, driven by noncommunicable disease². Regionally, the gap correlates with life expectancy, GDP, and chronic disease burden; Africa shows the narrowest gap but the fastest expansion⁴⁵. Gender comparisons should be read cautiously, since the raw numbers can mask underlying differences in survival and disability⁶.

What medical interventions can close the gap?

None is proven in humans yet. Rapamycin extends lifespan robustly in animals¹², and senolytics like dasatinib plus quercetin show early human activity¹³, but both remain research tools with unresolved safety questions¹⁵. The interventions with the strongest human evidence are still lifestyle-based ones affecting metabolic, inflammatory, and cardiovascular markers²³.

Where this leaves us

The central finding of longevity science is also its most sobering: we have gotten much better at postponing death than at postponing disease. The result is a healthspan-lifespan gap that is universal, sizable, and — for now — still widening².

A productive response is not to chase experimental drugs whose human evidence is thin, but to act on the levers the data support. Metabolic health, movement, strength, sleep, and stress sit at the intersection of the biomarkers most tied to how well and how long we live⁹²³. The emerging science of rapamycin, senolytics, and aging biomarkers is genuinely exciting and worth watching — but it remains a research frontier, not yet a foundation for practice.

In much of the world, living longer is largely a solved problem. Living well through those extra years is the question still open.

Related reading

• Exercise for healthspan
• Evidence-based nutrition framework
• Sleep and health: an evidence-based guide
• How to read health research using the evidence hierarchy

Sources

1. JAMA Internal Medicine, 2016: Lifespan and Healthspan: Past, Present, and Promise
2. JAMA Network Open, 2024: Global Healthspan-Lifespan Gaps Among 183 World Health Organization Member States
3. Nature Communications Medicine, 2025: The US Has the Largest Healthspan-Lifespan Gap of Any Country Tracked by the WHO
4. Nature Communications Medicine, 2025: Healthspan-Lifespan Gap Differs in Magnitude and Disease Contribution Across World Regions
5. NPJ / PMC, 2025: Healthspan-Lifespan Gap Differs in Magnitude and Disease Contribution Among World Regions
6. BMJ Open, 2025: Gender Gaps in Healthy Life Expectancy as Indicators of Inequality for Health
7. Nature Communications, 2025: Compression of Morbidity by Interventions That Steepen the Survival Curve
8. Nature Aging, 2021: Longevity Leap: Mind the Healthspan Gap
9. Communications Medicine, 2025: Comprehensive Cross-Sectional and Longitudinal Comparison of Markers of Biological Aging
10. Nature Medicine, 2024: Validation of Biomarkers of Aging
11. Nature Medicine, 2024: A Framework to Standardize Biomarkers of Aging and Accelerate Clinical Adoption
12. Aging Cell, 2025: Rapamycin, Not Metformin, Mirrors Dietary Restriction-Driven Lifespan Extension Across Vertebrates
13. EBioMedicine, 2019: Senolytics Decrease Senescent Cells in Humans: Dasatinib plus Quercetin in Diabetic Kidney Disease
14. Geroscience, 2023: Long-Term Dasatinib plus Quercetin Effects on Aging Outcomes in a Nonhuman Primate Model
15. Frontiers in Cardiovascular Medicine, 2025: Cardiovascular Aging: From Molecular Mechanisms to Targeted Therapies
16. Nature Aging, 2025: Plasma-Based Brain Age as a Potential Biomarker for Cognitive Decline and Age-Related Diseases
17. Current Gerontology and Geriatrics Research, 2024: Biological and Physical Performance Markers for Early Detection of Cognitive Impairment
18. Frontiers in Neuroscience, 2021: Aging Biomarkers and the Brain
19. Clinical Interventions in Aging, 2025: Understanding Cognitive Decline in Aging: Mechanisms and Interventions
20. International Journal of Environmental Research and Public Health, 2022: Economic Implications of Health Care Burden for Elderly Population
21. Nature Aging, 2021: The Economic Value of Targeting Aging
22. Frontiers in Public Health, 2023: How Heavy Is the Medical Expense Burden Among Older Adults With Chronic Diseases?
23. EBioMedicine (The Lancet), 2021: Targeting Multimorbidity: Using Healthspan and Lifespan to Identify Biomarkers of Ageing
24. Journals of Gerontology: Series A, 2025: An Expert Consensus Statement on Biomarkers of Aging for Use in Intervention Studies
25. Gerontology, 2015: A Proposed Panel of Biomarkers of Healthy Ageing